Inferior Vena Cava Collapsibility Index in Severe Acute Decompensated Heart Failure as Predictor of In-Hospital Mortality

Ender Özgün Çakmak1, Emrah Bayam1, Elnur Alizade1, Muzaffer Kahyaoğlu2, Mehmet Çelik1, Samet Uysal1, İbrahim Akın İzgi1, Cevat Kırma1

1 Department of Cardiology, Kartal Kosuyolu High Specialization Training and Research Hospital, Istanbul, Turkey
2 Department of Cardiology, Gaziantep Abdulkadir Yuksel State Hospital, Gaziantep, Turkey

ABSTRACT

Introduction: The aim of this study was to assess the relation between the diameter and collapsibility of the inferior vena cava (IVC), other markers, clinical variables and in-hospital mortality in patients hospitalized with severe acute decompensated heart failure (ADHF).

Patients and Methods: An observational prospective study was conducted that included patients hospitalized with severe ADHF from April 2019 to March 2020. Inferior vena cava collapsibility index (IVCCI) was measured during the first 12 hours at admission. The endpoint was in-hospital mortality.

Results: Two hundred thirty one patients hospitalized for ADHF, 28 (12.1%) of them died during hospitalization and formed non-survivors group. There were significant difference between non-survivors and survivors in case of IVVCI (21.25 ± 5.6 vs. 36.2 ± 18.3; p= 0.01 respectively). According to multivariate analysis IVCCI remained independent predictor of in-hospital mortality (p< 0.05). An IVCCI less than 23 predicted in-hospital mortality with 69% sensitivity and 75% specificity.

Conclusion: In patients hospitalized with acute decompensated heart failure, a low IVCCI by 2D echocardiography at the time of admission is associated with a higher in-hospital mortality.

Key Words: Inferior vena cava collapsibility; heart failure; hospitalization; mortality.

INTRODUCTION

Acute decompensated heart failure (ADHF) is a sudden and progressive worsening syndrome of heart failure (HF), which is characterized by exacerbation of HF signs and symptoms resulting in the need for urgent treatment with hospitalization. ADHF constitutes...
a complex clinical syndrome, representing a broad spectrum of diseases and statuses with heterogeneous clinical presentations. ADHF poses a unique medical burden of high morbidity and mortality. The continued high mortality rate for patients hospitalized with ADHF provides a compelling indication for accurate risk stratification for potentially improving individual management and hospital outcome.

In patients admitted due to ADHF, the degree of congestion is of prognostic relevance (1). Congestion is defined as elevated left ventricular filling pressure and further subclassified in hemodynamic and clinical congestion depending on the absence or presence of clinical signs and symptoms of congestion (2). According to a scientific statement of the European Society of Cardiology, the reference standard for evaluation of hemodynamic congestion is cardiac catheterization to measure right atrial pressure (RAP) and pulmonary capillary wedge pressure (PCWP) (2). However, the routine use of cardiac catheterization is limited due to its invasive nature, other markers of decongestion are needed in order to guide physicians during decongesting therapy. Based on this, echocardiography guidelines recommend ultrasound assessment of the inferior vena cava (IVC) to estimate RAP (3). Considerable efforts have been made to stratify patient risk in order to identify patients with a poor prognosis in whom closer surveillance or more intense treatment might improve outcome or to identify potential mechanisms driving outcome that might be targets for therapy. Published data from studies indicate that IVC dilation and collapsibility may be associated with early readmission and all cause mortality after hospitalization in patients with ADHF (4-6). In this study we assessed the importance of IVC measurements as a marker for in-hospital mortality other than all cause mortality in severe ADHF patients.

**PATIENTS and METHODS**

A prospective and observational study included patients from April 2019 to March 2020. We enrolled 231 patients for acute decompensated chronic HF or new onset ADHF, functional class per New York Heart Association (NYHA) classification grade III or IV and without signs of acute coronary syndrome. The study was approved by the institutional ethical board and informed consent was obtained from all patients. The diagnosis of ADHF was performed by medical history and physical examination, in addition to NT-proBNP assay (7). The exclusion criteria were; need for non-invasive positive pressure ventilation or intubation, cardiogenic shock with end-organ hypoperfusion plus systolic blood pressure < 90 mmHg, inability to undergo echocardiography in 12 hours of admission, presenting predominantly as right-side HF, ADHF due to significant arrhythmias, acute pulmonary embolism, acute exacerbation of chronic pulmonary disease, advanced renal failure (glomerular filtration rate < 30 mL/min/1.73 m²), pregnancy, myocarditis, constrictive pericarditis, pericardial effusion, chronic hepatitis. Primary end point was in-hospital mortality.

On admission, the following data were recorded: age, gender, blood pressure, heart rate, oxygen saturation, medications, electrocardiogram, NT-terminal pro-BNP, hemoglobin, albumin, creatinine, sodium. Glomerular filtration rate was calculated according to the Modification of Diet of Renal Disease (MDRD-4) formula. The presence of diabetes mellitus, hypertension, coronary artery disease, valvular heart disease were also noted.

A comprehensive echocardiography was performed during the first 12 hours of admission by an expert cardiologists who were not involved in the treatment of the patients. Conventional two-dimensional echocardiography was performed using commercially available equipment (Vivid 7, General Electric Vingmed Ultrasound, Horten, Norway) with a 2.5 MHz transducer. Left ventricular ejection fraction (LVEF) was determined by the biplane Simpson’s method. The measurement of IVC diameters were performed with the patient in the supine position with elevated 30 degrees (8). The transducer was placed in the subxiphoidal region, and long and short axis views of the IVC were obtained just below the diaphragm in the hepatic segment. IVC diameters were measured within 2 cm from the right atrium; the minimum diameter was obtained during full forced inspiration, whereas the maximum diameter was obtained during expiration. The inferior vena cava collapsibility index (IVCCI) was determined by the ratio of the minimum and maximum diameters of the IVC according to the following formula (9): IVCCI= (maximum diameter of the IVC-minimum diameter of the IVC)/(maximum diameter of the IVC).

Inpatient medical management by the primary medical team was guided by protocols from the ESC guidelines on the treatment of ADHF (10). The patients who did not respond to medical management and died formed the non-survivor group, the patients who responded to medical treatment and were discharged formed the survivor group.

Statistical analyses were performed using SPSS 20.0 statistical package (SPSS Inc., Chicago, IL). Categorical variables (demographics and comorbidities) were given as counts and percentages. Continuous variables and IVC measurements were given as means with standard deviations, Kolmogorov-Smirnov tests were used to compare continuous variables.
between groups. The Student’s t-test and Mann-Whitney U test was employed to compare continuous variables, the chi-square or Fisher’s exact test was employed to compare categorical variables, and Pearson’s correlation test was employed to evaluate the relationship between pairs of continuous variables. Cox proportional hazards analysis was conducted to assign the independent risk factors for in-hospital mortality. Optimal cut off values for IVCCI for in hospital mortality prediction were determined by establishing receiver operating characteristic (ROC) curves and calculating the area under the curve (AUC) for distinct IVCCI diameters. Survival was analyzed using the Kaplan-Meier (K-M) method using cumulative survival curves with the log-rank (Mantel-Cox) test. p< 0.05 was considered to be statistically significant.

RESULTS

Two hundred thirty one patients admitted with severe ADHF were included in the study. Baseline demographic, clinical, laboratory and comprehensive echocardiographic characteristics of in hospital survivors and non-survivors are demonstrated in Table 1. All patients were NYHA class III or IV with a mean age of 70.3 ± 12.1 years. Some 28.5% of the patients had LVEF ≥ 50% as preserved LVEF (68 patients, data not shown). Twenty eight (12.1%) patients died in hospital formed non-survivors group and they were older (74.3 ± 10 vs. 69.7 ± 12.2 years; p= 0.05). The prevalence of diabetes mellitus, hypertension, coronary artery disease and valvular heart disease did not differ between the groups. There were significant difference between the clinical characteristics

Table 1. Baseline characteristics of the study population

<table>
<thead>
<tr>
<th></th>
<th>All patients (n= 231)</th>
<th>Survivals (n= 203)</th>
<th>Non-survivals (n= 28)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>70.3 ± 12.1</td>
<td>69.7 ± 12.2</td>
<td>74.3 ± 10</td>
<td>0.05</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td>119 (51.5)</td>
<td>105 (51.7)</td>
<td>14 (50)</td>
<td>0.8</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>140 (60.6)</td>
<td>124 (61)</td>
<td>16 (57)</td>
<td>0.5</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>162 (70.1)</td>
<td>144 (70.9)</td>
<td>18 (64.2)</td>
<td>0.4</td>
</tr>
<tr>
<td>Coronary artery disease, n (%)</td>
<td>77 (33.3)</td>
<td>68 (33.5)</td>
<td>9 (32.1)</td>
<td>0.7</td>
</tr>
<tr>
<td>Valvular heart disease, n (%)</td>
<td>28 (12)</td>
<td>25 (12.3)</td>
<td>3 (10.8)</td>
<td>0.4</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>127 ± 30.2</td>
<td>129.4 ± 29.9</td>
<td>113.75 ± 27.2</td>
<td>0.01</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>97.4 ± 22</td>
<td>97.9 ± 22.4</td>
<td>93.75 ± 19.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Saturation O2 (%)</td>
<td>93.4 ± 6.4</td>
<td>93.8 ± 5.2</td>
<td>90.2 ± 12</td>
<td>0.006</td>
</tr>
<tr>
<td>Heart rate (minutes)</td>
<td>94 ± 14</td>
<td>92.6 ± 14.3</td>
<td>101 ± 6.9</td>
<td>0.03</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>8199.2 ± 895.7</td>
<td>8037.9 ± 793.8</td>
<td>9368.7 ± 712.2</td>
<td>0.01</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>11.2 ± 2.38</td>
<td>11.1 ± 2.4</td>
<td>11.85 ± 2.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>35.1 ± 4.2</td>
<td>34.8 ± 4.4</td>
<td>35.4 ± 1.3</td>
<td>0.7</td>
</tr>
<tr>
<td>eGFR (%)</td>
<td>54.1 ± 26.6</td>
<td>56.1 ± 27.7</td>
<td>39.2 ± 14</td>
<td>0.02</td>
</tr>
<tr>
<td>Sodium (mmol/L)</td>
<td>133.7 ± 6.5</td>
<td>134.4 ± 6.5</td>
<td>128.5 ± 6.4</td>
<td>0.01</td>
</tr>
<tr>
<td>Left ventricle ejection fraction (%)</td>
<td>35.3 ± 12.9</td>
<td>36.2 ± 12.4</td>
<td>30 ± 14.8</td>
<td>0.01</td>
</tr>
<tr>
<td>Left atrium diameter (cm)</td>
<td>4.59 ± 0.54</td>
<td>4.5 ± 0.5</td>
<td>4.8 ± 0.6</td>
<td>0.03</td>
</tr>
<tr>
<td>Pulmonary artery systolic pressure (mmHg)</td>
<td>40.9 ± 11.6</td>
<td>39.8 ± 11.2</td>
<td>48.75 ± 11.6</td>
<td>0.01</td>
</tr>
<tr>
<td>IVC diameter, expiration (cm)</td>
<td>2.43 ± 0.5</td>
<td>2.4 ± 0.5</td>
<td>2.5 ± 0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>IVC diameter, inspiration (cm)</td>
<td>1.61 ± 0.63</td>
<td>1.5 ± 0.6</td>
<td>1.9 ± 0.3</td>
<td>0.02</td>
</tr>
<tr>
<td>IVC collapsibility index (%)</td>
<td>34.3 ± 0.63</td>
<td>36.2 ± 18.3</td>
<td>21.25 ± 5.6</td>
<td>0.01</td>
</tr>
</tbody>
</table>

eGFR: Estimated glomerular filtration rate, IVC: Inferior vena cava.
of survivors and non-survivors groups. On admission, non-survivors had higher NT-proBNP levels (9368.7 ± 712.2 vs. 8037.9 ± 793.8; p= 0.01), lower sodium levels (128.5 ± 6.4 vs. 134.4 ± 6.5; p= 0.01) and lower LVEF (30 ± 14.8 vs. 36.2 ± 12.4). Mean IVC diameters were 2.43 ± 0.5 cm for expiration and 1.61 ± 0.63 cm for inspiration, mean IVCCI was 34.3% ± 0.63. There were significant difference between non-survivors and survivors in case of IVVCI (21.25 ± 5.6 vs. 36.2 ± 18.3; p= 0.01 respectively). To determine the independent predictors of in-hospital mortality, we performed multivariable logistic regression analysis by using variables age, LVEF, NT-proBNP and IVCCI (Table 2). These variables are also statistically significant in previous studies for predicting prognosis. Only NT-proBNP (HR: 1.002, 95% CI: 1.001-1.003, p= 0.001) and IVCCI (HR: 0.892, 95% CI: 0.824-0.964, p= 0.004) were independent predictors of in-hospital mortality. We performed a ROC analysis and determined a cutoff value for IVCCI of < 23% (69% sensitivity and 75% specificity) with area under the curve (AUC) value 0.733 (95% CI: 0.661-0.804; p< 0.001) for predicting in hospital mortality (Figure 1). Kaplan-Meier test resulted shorter survival in patients with IVCCI < 23% (log-rank, p< 0.001) (Figure 2).

**DISCUSSION**

Our study found that a depressed IVCCI at admission is associated with a poor prognosis after hospitalization for severe ADHF. Patients with an IVCCI less than 23% at admission had higher in-hospital mortality.

The IVC diameter is a brief assessment of cardiac function, also a sign of venous congestion. Systolic or diastolic left ventricular dysfunction ends up left atrial hypertension, the pressure is delivered back across the pulmonary circulation to result in pulmonary arterial hypertension that combines any preexisting dysfunction of right ventricle and aggravates tricuspid regurgitation(11). RAP and IVC distension increases as consequence of these stresses. If congestion is the hallmark of ADHF, then distension of the great veins may be the best indication on imaging. IVCCI can appropriately be used to estimate RAP semiquantitatively(3). We have shown that IVC dilated and the attenuated IVCCI is incorporated with a worse prognosis of in-hospital mortality in ADHF patients.

Despite the crucial role of physical examination, physicians are becoming less skilled at physical examination and dependent on modern technology(12). It is noteworthy that the IVC status

| Table 2. Multivariate analysis of in hospital mortality |
|---------------------------------|-----------|-----------|-----------|
| Hazard ratio  | 95% CI     | p value   |
| Left ventricle ejection fraction (%) | 1.003     | 0.962-1.003| 0.8       |
| Age (years)   | 1.028     | 0.976-1.083| 0.3       |
| NT-proBNP (pg/mL) | 1.002     | 1.001-1.003| 0.001     |
| IVC collapsibility index (cm)     | 0.892     | 0.824-0.964| 0.004     |

IVC: Inferior vena cava, CI: Confidence interval.
can be accurately evaluated by a novice in imaging, whereas elevated jugular venous pressure (JVP) is not easily identified even by experienced cardiologists. Therefore, IVCCI assessment may be a plausible alternative for JVP in estimating RAP, treatment inducement, and prediction of outcomes, and for patients two-dimensional echocardiography performed routine measurement of IVCCI is legitimate.

The IVC assessments is usually simple to perform in patients with HF and has low inter-observer alteration. Instead of invasive catheterization and complications such as air embolism, pneumothorax, or injury of great vessels, when echocardiography is available, IVC measurements may supply similar data in HF patients. Of note, IVCCI assessment can be a reasonable representative for jugular venous pressure regardless of the presence of ADHF in the diagnosis and prognosis.

In patients with HF, RAP elevation as predicted by the IVCCI was outstandingly associated with poor clinical outcomes, the IVCCI estimated the regulation of diuretics more precisely than clinical examination. Also, a recent study showed IVCCI could be used for selection of diuretic strategy. These point out the clinical practicality of the IVCCI regardless of its relationship with RAP in HF.

There is no research directly examining in-hospital mortality and IVCCI correlation in ADHF patients. Ours is the first study to investigate the relationship between IVC measurements and other markers of in-hospital mortality in patients with ADHF. Two recent studies evaluated IVCCI and mortality in hospitalized ADHF patients but as a prognostic marker of combined event of mortality and HF readmission during the 180 days of follow up. Both concluded a low IVCCI indicative of IVC congestion, as a basic and helpful tool that helps to rapidly and non-invasively stratify the prognosis of these patients in the onset of medical care, and consolidate with adverse outcomes in patients with a wide spectrum of cardiovascular diseases.

Our study demonstrated that in terms of prognosis, the IVCCI < 23% at admission as a response of systemic congestion was associated with an increased possibility of mortality at initial hospitalization. The lack of IVC collapse appears to be more significant than the degree of maximum diameter. Also in our study plasma NT-proBNP levels were predictive of death after hospitalization for ADHF like in previous studies. NT-proBNP level is predictive of in-hospital mortality in patients with either reduced or preserved LVEF independent of other clinical and laboratory variables.

There are few important differences with current study and the above mentioned ADHF studies which reinforced the relationship between congestion and the prognosis. First, all of the present study patients were hospitalized with NYHA functional class III or IV, higher than 47% of Romano et al. and 19% of Laorden et al. Second, the predominant HF type in our study was heart failure with reduced ejection fraction, however both of other studies had predominantly patients with preserved ejection fractions. Third our sample size is more than the above mentioned hospitalized ADHF and prognosis IVCCI studies. Consequently relatively high event rate, low IVCCI in outcome patients and predictive levels of NT-proBNP which is inconsistent with prior studies may be explained by these differences.

In our study, in-hospital mortality rate was 12.1% which is higher than studies including hospitalized ADHF patients; 6.7% and 7.6% in the most recent ones, and 3.8% in two well known researches. In a multi-center, prospective in-hospital mortality assessed study, indicators of outcome included advanced age, low admission SBP and sodium levels, high heart rate, and elevated creatinine levels. The higher mortality rates in our study may be because of all hospitalized patients possessed most of these indicators and additionally all being severe ADHF (NYHA functional class III or IV). Esc-HF Pilot study patients had mean 133 mmHg SBP and 88/min HR (127 mmHg SBP and 94/min in our cohort) with only 28% severe ADHF. A newly published study reported 7.6% in-hospital mortality having 70% severe ADHF patients with 88/min HR still lower indicator values than our cohort. As a result more tachycardia and symptomatic patients in our study eventuated poor in-hospital prognosis. In addition, lower mean LVEF value and low usage of HF medications in our patients might be other reasons for high in-hospital mortality.

**STUDY LIMITATIONS**

Our study has some limitations. The research was conducted at a tertiary referral high volume hospital where excessive rate of severe and complicated patients referred which may limit the generalization of its conclusions. Our study was not a prospective randomized study, unmeasured variables if might have been available could effect the findings. Additionally, we report only in-hospital mortality and our results did not approve for post discharge conclusions. Furthermore, our registry data identify relationships between patient versatility and in-hospital mortality and did not describe cause and effect correlations.
CONCLUSION

The current study’s findings suggests that determining IVCCI < 23% during the first 12 hours of admission is an independent risk factor for in-hospital mortality of severe ADHF. The IVC measurements are easy to perform and ensures similar prognostic data as plasma concentrations of NT-proBNP. By contrast, measurement of LVEF did not contribute to prognostic information. Further studies needed to evaluate IVC characteristics with signs of severe ADHF in order to stratify the other risk factors for these patients.

Informed Consent: Informed consent was obtained.

Conflict of Interest: The authors have no conflicts of interest to declare

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES


7. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69. [Crossref]


10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200. [Crossref]

11. Donny T, Goode KM, Kallivikbacka-Bennett A. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J 2010;31:2280-90. [Crossref]

12. Fletcher RH, Fletcher SW. Has medicine outgrown physical diagnosis? Ann Intern Med 1992;117:786-7. [Crossref]


15. Wu X, Studer W, Erb T. Competence of the internal jugular vein valve is damaged by cannulation and catheterization of the internal jugular vein. Anesthesiology 2000;93:319-24. [Crossref]


19. Gundersen GH, Norekval TM, Haug HH. Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study. Heart 2016;102:29-34. [Crossref]


